[go: up one dir, main page]

MX2017002361A - Mono-, di-, o polisacarido usado como inhibidor de metal en la preparacion del agente enfocado funcionalizado con quelato galio 68 (68ga). - Google Patents

Mono-, di-, o polisacarido usado como inhibidor de metal en la preparacion del agente enfocado funcionalizado con quelato galio 68 (68ga).

Info

Publication number
MX2017002361A
MX2017002361A MX2017002361A MX2017002361A MX2017002361A MX 2017002361 A MX2017002361 A MX 2017002361A MX 2017002361 A MX2017002361 A MX 2017002361A MX 2017002361 A MX2017002361 A MX 2017002361A MX 2017002361 A MX2017002361 A MX 2017002361A
Authority
MX
Mexico
Prior art keywords
polisacaride
chalate
galio
focused
mono
Prior art date
Application number
MX2017002361A
Other languages
English (en)
Other versions
MX388098B (es
Inventor
Wouters Ludovic
KAISIN Geoffroy
LUXEN André
LÉONARD Marc
Voccia Samuel
Original Assignee
Anmi S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anmi S A filed Critical Anmi S A
Publication of MX2017002361A publication Critical patent/MX2017002361A/es
Publication of MX388098B publication Critical patent/MX388098B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Radiation-Therapy Devices (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere al uso del inhibidor de metal en las reacciones de marcaje radiactivo usando metales radiactivos.
MX2017002361A 2014-08-29 2015-07-28 Mono-, di-, o polisacarido usado como inhibidor de metal en la preparacion del agente enfocado funcionalizado con quelato galio 68 (68ga). MX388098B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE2014/0653A BE1021191B1 (fr) 2014-08-29 2014-08-29 Kit pour radiomarquage.
PCT/EP2015/067213 WO2016030104A1 (en) 2014-08-29 2015-07-28 Mono-, di- or polysaccharide used as metal inhibitor in the preparation of 68ga-chelate-functionalized targeting agent

Publications (2)

Publication Number Publication Date
MX2017002361A true MX2017002361A (es) 2017-09-15
MX388098B MX388098B (es) 2025-03-19

Family

ID=52396314

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017002361A MX388098B (es) 2014-08-29 2015-07-28 Mono-, di-, o polisacarido usado como inhibidor de metal en la preparacion del agente enfocado funcionalizado con quelato galio 68 (68ga).
MX2017002362A MX379367B (es) 2014-08-29 2015-07-28 Kit para marcaje radiactivo con galio 68 (68ga) que comprende un inhibidor de metal.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017002362A MX379367B (es) 2014-08-29 2015-07-28 Kit para marcaje radiactivo con galio 68 (68ga) que comprende un inhibidor de metal.

Country Status (20)

Country Link
US (6) US11040120B2 (es)
EP (4) EP3862025A1 (es)
JP (2) JP6552622B2 (es)
CN (2) CN106794265B (es)
AU (7) AU2015309187B2 (es)
BE (1) BE1021191B1 (es)
BR (3) BR112017003710B1 (es)
CA (3) CA2958471C (es)
DK (1) DK3185911T3 (es)
ES (2) ES2856030T3 (es)
FR (1) FR25C1028I1 (es)
HU (1) HUE053971T2 (es)
IL (2) IL250736B (es)
MX (2) MX388098B (es)
NZ (1) NZ729293A (es)
PL (1) PL3185911T3 (es)
PT (1) PT3185911T (es)
RU (2) RU2724894C2 (es)
WO (2) WO2016030103A1 (es)
ZA (1) ZA201702152B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1021191B1 (fr) 2014-08-29 2015-10-27 Anmi S.A. Kit pour radiomarquage.
US11027030B2 (en) 2014-08-29 2021-06-08 Anmi S.A. Kit for radiolabelling
GB201504064D0 (en) * 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
CN106377527B (zh) * 2016-09-05 2019-02-26 郑州大学 开链吡啶羧酸衍生物H2dedpa在抗菌领域的应用
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
WO2018204872A2 (en) 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
US11191854B2 (en) 2017-05-05 2021-12-07 Centre For Probe Development And Commercialization Pharmacokinetic enhancements of bifunctional chelates and uses thereof
SG11202005332WA (en) * 2017-12-08 2020-07-29 Ecs Biotracker Sarl Radiolabeled progastrin in cancer diagnosis
WO2019246445A1 (en) * 2018-06-20 2019-12-26 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
CN110787186B (zh) * 2019-10-22 2020-11-17 华中科技大学 一种Ga3+/PDA靶向协同抗菌纳米材料、其制备和应用
IT202000032603A1 (it) 2020-12-29 2022-06-29 Univ Degli Studi Di Bari Aldo Moro Kit freddi a base di ligandi del psma per l’allestimento di radiofarmaci.
MX2023014255A (es) 2021-05-31 2024-01-18 Telix Pharmaceuticals Innovations Pty Ltd Antigeno de membrana especifico de la prostata mejorado dirigido a radiofarmaceuticos y sus usos.
MX2024000041A (es) 2021-06-29 2024-04-26 Life Molecular Imaging Ltd Un kit novedoso para la preparación radiofarmacéutica de un conjugado de direccionamiento funcionalizado con quelato, marcado con radiometal.
US20250360235A1 (en) * 2024-05-23 2025-11-27 Telix Innovations SA Radiolabelling kit and method for radiolabelling

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7902342A (nl) 1979-03-26 1980-09-30 Byk Mallinckrodt Cil Bv Isotopengenerator.
AU2002365649A1 (en) * 2001-11-28 2003-06-17 Immunomedics, Inc. Anti-dota antibody
US7011816B2 (en) * 2001-12-26 2006-03-14 Immunomedics, Inc. Labeling targeting agents with gallium-68 and gallium-67
SI2301587T1 (sl) * 2002-03-01 2014-11-28 Dyax Corp. KDR in VEGF/KDR vezavni peptidi in njihova uporaba pri diagnozi
US7597876B2 (en) * 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
GB0308408D0 (en) 2003-04-11 2003-05-21 Amersham Plc Microwave activation
KR101106533B1 (ko) 2003-07-24 2012-01-20 브라코 이미징 에스.피.에이. 안정한 방사성의약 조성물 및 제조 방법
BRPI0606395A2 (pt) 2005-01-05 2009-06-23 Univ Texas conjugados para ambas imagem e radioquimioterapia: composição, fabricação e aplicações
US8545809B2 (en) 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
US9408928B2 (en) * 2007-03-27 2016-08-09 Radiomedix, Inc. Compositions for targeted imaging and therapy
FR2942227B1 (fr) * 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
US20120164111A1 (en) * 2009-04-14 2012-06-28 Kurt Osther Novel post-translational fibrinogen variants
US20120121509A1 (en) 2009-06-05 2012-05-17 The General Hospital Corporation Vital fluorochrome conjugates and methods of use
US8951064B2 (en) 2010-12-14 2015-02-10 Ideal Industries, Inc. Terminal structures for wiring devices
ITFI20110180A1 (it) * 2011-08-12 2013-02-13 Advanced Accelerator Applic S A Processo per la preparazione di complessi di 68ga.
US9161998B2 (en) * 2012-05-18 2015-10-20 Zentralklinik Bad Berka Gmbh Method and kit for preparing a radiopharmaceutical
EP2912459A2 (en) * 2012-10-25 2015-09-02 Life Technologies Corporation Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins
US11027030B2 (en) 2014-08-29 2021-06-08 Anmi S.A. Kit for radiolabelling
BE1021191B1 (fr) 2014-08-29 2015-10-27 Anmi S.A. Kit pour radiomarquage.
CN104830316B (zh) * 2015-05-11 2017-02-01 厦门大学 一种用于核素标记的靶向探针及其制备方法和应用
ITUA20163207A1 (it) 2016-05-06 2017-11-06 Azienda Ospedaliera Di Reggio Emilia Arcispedale Santa Maria Nuova Preparazione in kit di radiofarmaci marcati con gallio-68

Also Published As

Publication number Publication date
RU2017109582A3 (es) 2018-12-20
JP6543343B2 (ja) 2019-07-10
PT3185911T (pt) 2021-03-22
CA2958475A1 (en) 2016-03-03
FR25C1028I1 (fr) 2025-09-19
JP2017530188A (ja) 2017-10-12
EP3185911A1 (en) 2017-07-05
MX388098B (es) 2025-03-19
PL3185911T3 (pl) 2021-08-23
CA2958471A1 (en) 2016-03-03
US20210275697A1 (en) 2021-09-09
CA3167294A1 (en) 2016-03-03
CN106659806A (zh) 2017-05-10
US12329829B2 (en) 2025-06-17
BE1021191B1 (fr) 2015-10-27
RU2017109583A (ru) 2018-10-01
IL250735B (en) 2021-04-29
CA2958471E (en) 2016-03-03
NZ729291A (en) 2021-03-26
AU2015309187A1 (en) 2017-03-09
EP3185912A1 (en) 2017-07-05
CN106794265B (zh) 2021-01-26
EP3862025A1 (en) 2021-08-11
AU2022202346A1 (en) 2022-04-28
RU2725627C2 (ru) 2020-07-03
HUE053971T2 (hu) 2021-07-28
ES2856030T3 (es) 2021-09-27
JP6552622B2 (ja) 2019-07-31
EP3185911B1 (en) 2020-12-30
RU2017109583A3 (es) 2018-12-26
AU2020220193A1 (en) 2020-09-10
AU2022202439A1 (en) 2022-05-05
AU2024205118A1 (en) 2024-08-15
US20210268131A1 (en) 2021-09-02
CA2958475C (en) 2022-07-12
US20220296735A1 (en) 2022-09-22
RU2017109582A (ru) 2018-10-01
RU2724894C2 (ru) 2020-06-26
IL250735A0 (en) 2017-04-30
WO2016030103A1 (en) 2016-03-03
BR112017003578A2 (pt) 2017-12-05
IL250736A0 (en) 2017-04-30
EP3862026A1 (en) 2021-08-11
US20220273827A1 (en) 2022-09-01
CN106794265A (zh) 2017-05-31
NZ729293A (en) 2022-04-29
CA2958471C (en) 2022-05-31
AU2020220194A1 (en) 2020-09-10
US11045563B2 (en) 2021-06-29
US11040120B2 (en) 2021-06-22
MX2017002362A (es) 2017-09-15
IL250736B (en) 2021-04-29
AU2015309188A1 (en) 2017-03-09
BR112017003710B1 (pt) 2021-12-14
ES2855991T3 (es) 2021-09-27
JP2017526745A (ja) 2017-09-14
US20180230069A1 (en) 2018-08-16
EP3185912B1 (en) 2020-12-30
BR112017003710A2 (pt) 2017-12-05
MX379367B (es) 2025-03-11
DK3185911T3 (da) 2021-03-15
US20180230068A1 (en) 2018-08-16
ZA201702152B (en) 2021-06-30
AU2015309188B2 (en) 2020-05-21
WO2016030104A1 (en) 2016-03-03
CN106659806B (zh) 2021-01-26
AU2015309187B2 (en) 2020-05-21
BR122021017474B1 (pt) 2023-10-10
CA3167294C (en) 2024-05-28
AU2022202439B2 (en) 2023-12-14
BR112017003578B1 (pt) 2023-12-26

Similar Documents

Publication Publication Date Title
MX2017002361A (es) Mono-, di-, o polisacarido usado como inhibidor de metal en la preparacion del agente enfocado funcionalizado con quelato galio 68 (68ga).
CL2023001910A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CL2016001963A1 (es) Heteroarilos inhibidores de syk
NI201800055A (es) Anticuerpos que se unen específicamente a pd-1 y sus usos.
CL2016002971A1 (es) Combinación.
TWD170353S (zh) 項鍊
MX2018009938A (es) Profarmacos de hormona paratiroidea (pth).
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
BR112016026942A2 (pt) geração de visualizações de direção curva por curva.
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
BR112016028543A2 (pt) composições orais contendo íons de metal.
MX2017003953A (es) Compuestos que contrarrestan el mal olor bajo, de cobertura-alta y metodos uso.
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
AR102677A1 (es) Composición que comprende sal de acil glutamato como agente tensoactivo primario o agente tensoactivo aniónico primario y polímeros estructurantes específicos
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
ITUB20152355A1 (it) Dispositivo di illuminazione, ad esempio per l'illuminazione di serre, e corrispondente procedimento di impiego
MX2017000862A (es) Formulacion de factor viii.
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
MX2016007592A (es) Composicion que comprende agente beneficioso y solvente aprotico.
PH12016502311A1 (en) Omega-3 analogues
CL2017001383A1 (es) Proceso para la fabricación de anhídrido carboxílico
ECSP18050673A (es) Formulaciones de giberelina en solución concentrada
ES2848285T8 (es) Composición sólida de descontaminación, su proceso de obtención y sus usos